

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.91120000103100784F)
(Incorporated in the People's Republic of China)

**ANNOUNCEMENT ON THE EXTENSION OF THE OPERATING PERIOD OF AN
ASSOCIATED COMPANY**

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

The Company wishes to announce that its associated company, Sino-American Tianjin SmithKline & French Lab., Ltd. (中美天津史克制药有限公司) (“TSKF”), a Sino-foreign joint venture limited liability company, has extended its operating period. As at the date of this announcement, the shareholders of TSKF are Haleon UK Services Limited, the Company and Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司), holding 55%, 25% and 20% equity interest in TSKF respectively. The original operating period of TSKF was set to expire on 22 September 2024. To facilitate thorough discussions and communications among the shareholders regarding the future operations of TSKF, all shareholders of TSKF have unanimously agreed to extend the operating period of TSKF to 30 June 2025 (the “**Extension**”). As at the date of this announcement, TSKF has completed the requisite changes in the industrial and commercial registration in respect of the Extension.

The Extension will not affect the production and operations of the Company. The Company will make timely disclosures in accordance with the requirements of applicable laws and regulations. Shareholders of the Company and potential investors are advised to make investments in a rational manner and be aware of the risks involved.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
1 August 2024